Clinical Trial Detail

NCT ID NCT02013804
Title A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors MedImmune LLC
Indications

melanoma

renal cell carcinoma

Therapies

MEDI0680

Age Groups: adult

No variant requirements are available.